A peptide with ACE inhibitory and antioxidant activities, screening method and application.
Patent Information
- Application Number
- CN202310304537.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2023-03-27
- Publication Date
- 2026-11-17
- Estimated Expiration
- 2043-03-27
Smart Images

Figure CN116355051B_ABST
Abstract
Description
Technical Field
[0001] This invention belongs to the field of biotechnology, specifically relating to an ACE inhibitory peptide derived from potassium chloride-low sodium salt pork sausage, its screening method, and its application. Background Technology
[0002] Hypertension plays a crucial role in the development of cardiovascular disease, a major chronic illness affecting the general population. Angiotensin-converting enzyme (ACE) is essential for regulating blood pressure via the renin-angiotensin system (RAS). Renin converts angiotensinogen to angiotensin I via the RAS pathway, while ACE converts Ang I (an inactive peptide) to Ang II, controlling vasoconstriction by binding to receptors in the blood vessel wall. Elevated levels of Ang II in endothelial cells induce oxidative stress, leading to reactive oxygen species (ROS) and various diseases. The antioxidant defense system is vital for protecting the body from oxidative damage. Therefore, inhibiting ACE activity and enhancing antioxidant capacity is an effective approach to treating hypertension and improving health.
[0003] Numerous food proteins have been reported as major sources of ACE-inhibiting peptides, such as cheddar cheese, palm kernel protein, walnut protein, and rabbit meat protein. Many ACE-inhibiting peptides also possess antioxidant capabilities. Meat is rich in protein, which produces peptides and amino acids during in vitro digestion. Due to its natural source, low toxicity, and diverse bioactivities, it has gained increasing attention. However, approximately 20%-30% of sodium in our daily diet comes from meat products. High-sodium diets can affect the renin-angiotensin-aldosterone system (RAS) and are associated with the development of chronic diseases. Potassium chloride (KCl) is the most widely used partial substitute for sodium chloride (NaCl). Studies have shown that partially replacing NaCl with KCl in Mozzarella cheese can increase ACE-inhibiting activity. Summary of the Invention
[0004] Obtaining more bioactive peptides that simultaneously possess ACE inhibitory and antioxidant activities for use in adjuvant antihypertensive drugs has always been an important direction in peptide research and development. This invention aims to predict the activity of identified peptides using a virtual screening method, combined with activity experiments, to obtain peptides that simultaneously possess ACE inhibitory and antioxidant activities.
[0005] Through extensive efforts and work, this invention has developed a screening method for ACE-inhibiting active peptides and obtained active peptides with both ACE-inhibiting and antioxidant activities through screening using this method, thus forming this invention.
[0006] This invention screened two polypeptides, P3 and P12, from the digestion products of potassium chloride-low sodium salt pork intestines, and obtained them simultaneously with ACE inhibitory activity and antioxidant activity. The amino acid sequence of P3 is Leu-Ile-Val-Gly-Phe-Ala-Tyr-Gly-His (LIVGFPAYGH), and the amino acid sequence of P12 is Ile-Val-Gly-Phe-Ala-Tyr-Gly-His (IVGFPAYGH).
[0007] In one embodiment of the present invention, a method for screening peptides with ACE inhibitory activity derived from potassium chloride-low sodium salt pork sausage is provided, comprising the following steps: (1) Preparation of potassium chloride-low sodium salt pork sausage Remove visible fat and connective tissue from the pork, mince the meat at 4°C, add NaCl and KCl to the minced meat, marinate at 4°C, pack into polyethylene casings and seal, then cook the sausages in a water bath, then immediately cool in ice water and store at 4°C. (2) Analysis of peptide composition of in vitro simulated digestion products Potassium chloride-low sodium salt pork sausage was chopped, added to phosphate buffer, and the pH was adjusted to 2.0 with 6 M HCl. Pepsin was added to simulate gastric digestion. After digestion, the pH was adjusted to 7.5 with 2 M NaOH to terminate gastric digestion. Then, pancreatic enzymes were added to start intestinal digestion. After the reaction was completed, the mixture was heated to terminate the reaction. The resulting mixture was centrifuged, the supernatant was separated, and the sample was analyzed by LC-MS / MS to obtain the composition of peptides in the digestion products. (3) Virtual screening and ACE inhibitory activity assay The bioactivity score of peptides was evaluated using PeptideRanker. Peptides were then molecularly docked with ACE to screen for peptides with the lowest ACE docking energy. Based on the screening results, peptides were prepared and their ACE inhibitory capacity was determined.
[0008] Preferably, in step (1), the amount of NaCl and KCl added is 1.95% NaCl and 1.05% KCl, the pickling time is 16h, and the water bath cooking is 30min in a water bath at 80℃.
[0009] Preferably, in step (2), the amount of pepsin added is 25000 U / g, and the conditions are a 37°C water bath with shaking at 150 rpm for 2 h; the amount of pancreatin added is 2200 U / g, and the conditions are a 37°C water bath with shaking at 150 rpm for 2 h.
[0010] Preferably, in step (3), peptides with a potential bioactivity score ≥0.8 and a predicted non-toxicity are selected by PeptideRanker and molecularly docked with ACE; peptides with a PeptideRanker score between 0.8 and 0.5 and a predicted non-toxicity are used to predict the absorption properties (HIA) of the active peptide using admetSAR, and peptides with a positive HIA are molecularly docked with the three-dimensional structure of ACE.
[0011] In one embodiment of the present invention, a method for screening peptides with ACE inhibitory activity derived from potassium chloride-low sodium salt pork sausage is provided, the method comprising the following steps: (1) Preparation of potassium chloride-low sodium salt pork sausage Remove visible fat and connective tissue from the pork, then grind it into a paste using a meat grinder (5 mm plate) at 4 °C. Add 1.95% NaCl and 1.05% KCl (w / w), mix well, and store at 4 °C for 16 h. Then, pack the mixture into polyethylene casings (20 mm in diameter, 30 g per sausage) sealed at one end with a snap-locking machine. Degas the casings and then seal the other end with the snap-locking machine. Cook the sausages in an 80 °C water bath for 30 min, then immediately cool them in ice water.
[0012] (2) In vitro simulated digestion Pork sausage was chopped (3mm × 3mm × 1mm), and 20 mL of phosphate-buffered saline (PBS, pH 7.0) was added. The pH was adjusted to 2.0 with 6 M HCl, and pepsin (25000 U / g) was added to simulate gastric digestion. The mixture was reacted in a constant-temperature shaking water bath at 150 rpm and 37°C for 2 h. Gastric digestion was terminated by adjusting the pH to 7.5 with 2 M NaOH, and then intestinal digestion was initiated by adding pancreatin (2200 U / g). The mixture was then reacted in a constant-temperature shaking water bath at 150 rpm and 37°C for 2 h. After the reaction was completed, the mixture was heated in a 95°C water bath for 15 min to terminate the reaction. The resulting mixture was centrifuged for 20 min (12,000 g, 4°C), and the supernatant was separated and stored at -40°C for subsequent use.
[0013] (3) LC-MS / MS analysis The digestion products were processed using a C-18 solid-phase extraction column, and the samples were analyzed by LC-MS / MS. The MS and MS / MS scan ranges were 350–2000 m / z and 200–2000 m / z, respectively. The obtained data were analyzed using pFIND software and the Uniprot database. Peptide sequences were determined by searching the Uniprot (https: / / www.uniprot.org / ), Swiss-Prot, and TreMBL databases for proteins originating from *Sus scrofa*.
[0014] (4) Virtual Filtering Peptide sequences identified by LC-MS / MS were evaluated using PeptideRanker. Peptides with a PeptideRanker score ≥0.8 and a ToxinPred prediction indicating non-toxicity were selected for molecular docking with ACE (PDB: 1o86). Peptides with PeptideRanker scores between 0.8 and 0.5 and a predicted non-toxicity were analyzed using admetSAR to predict the bioavailability (HIA). Peptides with a positive HIA were molecularly docked with the ACE three-dimensional structure (PDB: 1o86), and the peptide with the lowest ACE docking energy was selected. The peptides were synthesized in solid phase using the Fmoc synthesis method on Wang resin, and the ACE inhibition rate was measured to obtain the target peptide.
[0015] In one aspect of the present invention, the two ACE inhibitory peptide sequences obtained by screening are LIVGFPAYGH and IVGFPAYGH, respectively.
[0016] In one aspect of the present invention, the active polypeptide of the present invention can be obtained by various polypeptide preparation methods well known in the art, preferably by solid-phase synthesis of polypeptides via Fmoc synthesis, preferably by controlled enzymatic hydrolysis and separation; preferably by constructing a polypeptide expression system through molecular biology and preparing it by biosynthesis; suitable hosts as expression vectors include microorganisms, cells, and viruses.
[0017] In one aspect, the present invention provides the use of the active polypeptide of the present invention in the preparation of ACE inhibitors and / or antioxidants. The formulation may be in various formulation forms, including liquid formulations, solid formulations, emulsions, liposomes, semi-solids, gels, etc.
[0018] In one aspect, the present invention provides the application of an active polypeptide obtained by the method for preparing a polypeptide with ACE inhibitory and antioxidant activity from a potassium chloride-low sodium salt pork sausage of the present invention in the preparation of a pharmaceutical product.
[0019] In one aspect, the present invention provides the use of a polypeptide with ACE inhibitory and antioxidant activity from potassium chloride-low sodium salt pork sausage in the preparation of a pharmaceutical product, wherein the pharmaceutical product further contains pharmaceutically acceptable excipients. Furthermore, the pharmaceutical product can be prepared into various acceptable dosage forms, including granules, capsules, tablets, and oral formulations.
[0020] In one aspect, the present invention provides a pharmaceutical preparation of the active polypeptide of the present invention for adjuvant antihypertensive or anti-inflammatory purposes. The active polypeptide of the present invention promotes NO release and reduces ET. 1. It has the function of releasing ACE2 and reducing the release of ACE, TGF-β1 and AngII; it has the ability to scavenge DPPH, ·OH and ABTS free radicals.
[0021] The peptides P3 and P12 obtained in this invention have ACE inhibitory and antioxidant activities. They have the ability to inhibit ACE activity and are mixed inhibitors, with IC50 values of 196.16±6.45μM and 150.88±5.24μM, respectively. At the same time, it was found that P3 and P12 have both ACE inhibitory and antioxidant activities.
[0022] In one aspect of the present invention, the present invention explores the binding sites of active peptides P3 and P12 with ACE protein through molecular docking, and finds that P3 and P12 can form hydrogen bonds with the amino acid active sites of the ACE active pocket.
[0023] Beneficial effects Compared with the prior art, the present invention has the following advantages: (1) By identifying the polypeptide sequence of the in vitro digestion product of potassium chloride-low sodium salt pork intestine, and combining virtual screening and in vitro activity experiment analysis, this invention obtained polypeptides P3 and P12 with ACE inhibition activity and antioxidant activity.
[0024] (2) The preparation process of the present invention has the advantages of simple operation and high safety. The P3 and P12 discovered in the present invention can be ideal raw material sources for drugs that have both antihypertensive and antioxidant properties, providing a theoretical basis and technical support for the development of bioactive peptides. Attached Figure Description
[0025] Figure 1 This invention screens peptides for ACE inhibition rate and IC50 value.
[0026] Figure 2 The inhibitory mechanism of ACE inhibitory peptides on ACE.
[0027] Figure 3 Molecular docking results of ACE inhibitory peptide with ACE.
[0028] Figure 4 Effects of ACE inhibitory peptides on the secretion of the renin-angiotensin system by Ang I-induced human umbilical vein endothelial cells (HUVECs).
[0029] Figure 5 Effects of ACE inhibitory peptides on NO and ET-1 secretion induced by Ang I in human umbilical vein endothelial cells (HUVECs).
[0030] Figure 6 Absorption and transport of ACE inhibitory peptides in Caco-2 cell monolayers.
[0031] Figure 7 A schematic flowchart of the screening method of the present invention. Detailed Implementation
[0032] The present invention will be further described below with reference to specific embodiments.
[0033] First, the main sources of materials and related descriptions of this invention will be introduced. Unless otherwise specified, other reagents and raw materials are all from commercially available conventional products.
[0034] Pepsin, FUJIFILM Wako Pure Chemical Corporation, Product No.: 9001-75-6.
[0035] Pancreatic enzyme, FUJIFILM Wako Pure Chemical Corporation, catalog number: 8049-47-6.
[0036] DMEM high glucose medium, VivaCell Biosciences, catalog number: C313-0500.
[0037] Premium fetal bovine serum, VivaCell Biosciences, catalog number: C04001-500.
[0038] ACE (from rabbit lung), Sigma Aldrich, part number: A667.
[0039] DPPH, Tokyo Chemical Industry, Part No.: D4313.
[0040] ABTS, Tokyo Chemical Industry, Part Number: A2166.
[0041] NO. Nanjing Jiancheng Biotechnology Institute, Product No.: A013-2-1.
[0042] ET-1, Jiangsu Enzyme-Label Biotechnology Co., Ltd., Product No.: MB-0998A.
[0043] Example 1: Screening of ACE inhibitory peptides derived from potassium chloride-low sodium salt pork sausage Visible fat and connective tissue were removed from the pork. The mixture was ground into a paste using a meat grinder (5 mm plate) at 4 °C. 1.95% NaCl and 1.05% KCl (w / w) were added, and the mixture was stored at 4 °C for 16 h. The paste was then packed into polyethylene casings (20 mm in diameter, 30 g per sausage) sealed at one end using a snap-locking machine. The casings were degassed, and the other end was sealed again using the snap-locking machine. The sausages were then cooked in an 80 °C water bath for 30 min, followed immediately by cooling in ice water. The pork sausages were chopped (3 mm × 3 mm × 1 mm), and 20 mL of phosphate-buffered saline (PBS, pH 7.0) was added. The pH was adjusted to 2.0 with 6 M HCl, and pepsin (25000 U / g) was added to simulate gastric digestion. The mixture was then reacted in a constant-temperature shaking water bath at 150 rpm and 37 °C for 2 h. Gastric digestion was terminated by adjusting the pH to 7.5 with 2 M NaOH, followed by intestinal digestion with trypsin (2200 U / g). The mixture was placed in a constant-temperature shaking water bath at 150 rpm and 37°C for 2 h. After the reaction, the mixture was heated in a 95°C water bath for 15 min to terminate the reaction. The resulting mixture was centrifuged for 20 min (12,000 g, 4°C), and the supernatant was separated. The digestion product was processed using a C-18 solid-phase extraction column, and the sample was analyzed by LC-MS / MS. The MS and MS / MS scan ranges were 350–2000 m / z and 200–2000 m / z, respectively. The obtained data were analyzed using pFIND software and the Uniprot database. Peptide sequences were determined by searching for proteins from *Sus scrofa* in the Uniprot (https: / / www.uniprot.org / ), Swiss-Prot, and TreMBL databases. Peptides with a PeptideRanker score ≥0.8 and a ToxinPred prediction indicating non-toxicity were selected for molecular docking with ACE (PDB: 1o86). Peptides with PeptideRanker scores between 0.8 and 0.5 and a predicted non-toxicity were then subjected to admetSAR prediction of their bioactivity properties (HIA). Peptides with a positive HIA were molecularly docked with the ACE three-dimensional structure (PDB: 1o86), and the peptide with the lowest ACE docking energy was selected. An illustrative screening process is shown below. Figure 7 As shown.
[0044] Table 1. Physicochemical properties analysis and molecular docking results of screened peptides. ; Example 2: Determination of the ACE inhibition rate of chemically synthesized peptides Fifteen peptides were synthesized via solid-phase synthesis, purified by high-performance liquid chromatography (HPLC), and their molecular weights were determined by LC-MS. The in vitro ACE inhibitory activity of the 15 peptides (1 mg / mL) was assessed; ACE activity is typically evaluated by measuring hippuric acid (HA) production. ACE and the substrate hippuryl-histidylleucine (HHL) were dissolved in 0.1 mol / L sodium borate buffer (pH 8.3, containing 0.3 mol / L NaCl). 30 μL of HHL (5 mM) was mixed with 10 μL of the peptide solution (1 mg / mL) and pre-incubated at 37°C for 10 min. Then, 30 μL of ACE solution (0.1 U, pre-incubated at 37°C for 10 min) was added, and the mixture was incubated at 37°C for 30 min. The reaction was terminated by adding 60 μL of 1 M HCl. The HA content in the mixture was determined by reversed-phase HPLC. Chromatographic conditions were as follows: C18 column (4.6 mm × 250 mm, 5 μm, Waters, USA); mobile phase: water (containing 0.1% trifluoroacetic acid): acetonitrile = 80:20 (v / v); isogradient elution; flow rate: 1 mL / min; DAD wavelength: 228 nm. The control group was prepared by replacing 10 µL of peptide solution with 10 µL of sodium borate buffer. The percentage inhibition of ACE activity was calculated using the following formula: ACE inhibition rate (%) = (A1 - A2) / A1 × 100% In the formula, A1 is the peak area of HA in the control group, and A2 is the peak area of HA after the addition of the inhibitor. The IC50 value refers to the inhibitor concentration that produces 50% inhibition of ACE. Each group was measured three times.
[0045] like Figure 1 As shown in Figure A, P3 (LIVGFPAYGH) and P12 (IVGFPAYGH) exhibited the strongest ACE inhibitory activities, at 88.36% and 89.15%, respectively. P3 (LIVGFPAYGH) contains 10 amino acids, of which the IVGFPAYGH (9 amino acids) sequence is identical to that of P12. The IC50 values of P3 and P12 were (196.16±6.45) μM and (150.88±5.24) μM, respectively. Figure 1 (Chinese BC).
[0046] Example 3: Determination of the ACE inhibition mode of ACE inhibitory peptides Lineweaver-Burk plots can be used for kinetic analysis of ACE inhibition. Different concentrations of substrate HHL (0.5, 1, 2, 5 mM) were pre-incubated with different concentrations of ACE-inhibiting peptides (0, 300, 500 μM / mL) at 37°C for 10 min, and then ACE solution (0.1 U, pre-incubated at 37°C for 10 min) was added to test the ACE-inhibiting activity of the peptides. Lineweaver-Burk plots were created with the reciprocal of substrate concentration (s) (1 / [s]) on the x-axis and the reciprocal of rate (1 / [v]) on the y-axis. The x-axis and y-axis cutoffs represent the reciprocals of Km and Vmax, respectively. The inhibition patterns of different peptide concentrations on ACE were obtained using linear fitting with Origin (9.1 software).
[0047] like Figure 2 As shown, the y- and x-axis intercepts increase with increasing concentrations of P3 (LIVGFPAYGH) and P12 (IVGFPAYGH), indicating that Km and Vmax values decrease with increasing LIVGFPAYGH and IVGFPAYGH concentrations (0-500 µM). This demonstrates that LIVGFPAYGH and IVGFPAYGH are mixed inhibitors, binding to both active and inactive sites of ACE and reducing ACE activity. The Vmax value of the ACE response decreases with increasing peptide concentration; at a peptide concentration of 0, the Vmax value of the ACE response is 4.41 μM / min. Figure 2 (AB). At the same concentration, the Vmax of IVGFPAYGH was lower than that of LIVGFPAYGH, indicating that IVGFPAYGH is more effective in inhibiting ACE, consistent with the IC50 value.
[0048] Example 4: Analysis of the docking binding site between ACE inhibitory peptide and ACE molecule The 3D structure of the peptide was plotted in Chemdraw Ultra 18.0, and then geometry optimized (energy minimization) was performed using Chem3D 18.0. The optimized structure was saved in Mol2 format as a small ligand molecule. The 3D structure of ACE (PDB: 1o86) was exported from the PDB database, and water molecules and other ligands were removed using PyMOL software. Subsequently, polar hydrogen atoms were added to the receptor protein using AutodockTools (version 1.5.6), and the result was saved as a pdbqt file. The stable conformation with the lowest binding energy was analyzed using PyMOL, and then a 3D plot was generated to show the optimal conformation for the interaction between the peptide and ACE. The 2D and 3D structures of the interaction between the peptide and ACE were obtained using BIOVIA Discovery Studio 2021 Client visualization software.
[0049] The active site of ACE contains three pockets: S1, S2, and S1'. The S1 pocket contains Ala354, Glu384, and Tyr523; the S2 pocket contains Gln281, His353, Lys511, His513, and Tyr520; and the S1' pocket contains Glu162. For example... Figure 3 As shown in Table 2, P3 (LIVGFPAYGH) forms hydrogen bonds with the amino acid residues Glu162 (S1′ pocket), Thr282, Ala354 (S1 pocket), Ala356, Glu376, His387, Asp415, Lys454, and Tyr523 (S1 pocket) of ACE. P12 (IVGFPAYGH) forms hydrogen bonds with the amino acid residues Asn66, Arg124, TYR135, TRP220, ALA356, GLU384 (S1 pocket), Ser516, Ser517, Tyr520 (S2 pocket), and Tyr523 (S1 pocket) of ACE. Figure 3 (AB). Hydrogen bonds are the main type of binding bond in peptide-ACE interactions. The synthetic ACE inhibitor lisinopril interacts with the amino acid residues of ACE: Tyr520, His353, Glu411, His387, Ala354, His383, Glu384, and Lys511.
[0050] Table 2. Binding sites of ACE-inhibiting peptides and their interaction with ACE. ; Example 5: Effect of ACE inhibitory peptide on Ang I-induced HUVEC cells HUVEC cells were cultured in DMEM high-glucose medium containing 10% (v / v) fetal bovine serum and 1% (v / v) penicillin / streptomycin at 37°C in an incubator with 5% CO2. Cells were passaged every 4 days, with a passage ratio of 1:3 when cells reached over 90% confluence. The medium was changed every 2 days depending on cell growth. HUVECs were cultured in 6-well plates at a density of 1 × 10⁵ cells / mL for 24 h. Cells were then treated with captopril (10 μmol / L) and peptides (100, 300 μmol / mL) for 4 h, followed by Ang I (1 μg / mL) for 12 h. At least 6 wells were used per group. Cells and culture medium were collected, and the levels of ACE, ACE2, Ang II, TGF-β1, NO, ET-1, and ET-1 mRNA expression were analyzed according to the kit instructions.
[0051] ACE, located on the endothelial cell membrane, is responsible for converting Ang I to Ang II. ACE inhibitory peptides inhibit the hydrolysis of Ang I to Ang II. ACE2, a homolog of ACE, primarily catalyzes the conversion of Ang II to Ang-(1-7). TGF-β1 plays a crucial role in the development of fibrotic diseases, exhibiting various biological functions, including recruiting inflammatory cells. Ang II is a major factor inducing and increasing TGF-β expression at injury sites. Figure 4 As shown in the AC diagram, compared with the Ang I model group, the captopril and peptide treatment groups (P3-100, P3-300, P12-100, P12-300) decreased the ACE and TGF-β1 levels and increased the ACE2 level in HUVECs cells (P<0.05). Compared with the Ang I model group, the captopril and peptide treatment groups (P3-100, P3-300, P12-100, P12-300) reduced the Ang II level in the HUVECs cell culture medium (P<0.05). Figure 4 (D). Compared with the Ang I model group, captopril, P3, and P12 increased the expression of ACE2 protein and decreased the expression of TGF-β1 protein in HUVECs. Figure 4 (EH). The results showed that P3 and P12 peptides could reduce the level of Ang I-induced Ang II production by HUVECs by inhibiting ACE activity, enhance the conversion catalytic ability of Ang II, and exhibit a dose-effect.
[0052] NO, as an important factor regulating vascular smooth muscle tone, antagonizes the effect of Ang II on vascular tone. ET-1 is one of the risk factors for endothelial dysfunction, hypertension, and atherosclerosis. Ang II can promote ET-1 secretion by upregulating ET-1 mRNA expression. After treating cells with P3 (LIVGFPAYGH) and P12 (IVGFPAYGH), the secretion levels of NO and ET-1 in the cytosol and the expression of ET-1 mRNA were detected. Figure 5 In the AB model group, compared with the Ang I model group, the captopril and peptide treatment groups (P3-100, P3-300, P12-100, P12-300) increased NO content and decreased ET-1 level (P<0.05). High-concentration peptide groups (P3-300 and P12-300) increased NO content and decreased ET-1 production compared with low-concentration peptide groups (P3-100 and P12-100), indicating a dose-effect relationship. Captopril and peptide P3 and P12 treatment groups reduced ET-1 mRNA expression in HUVECs. Figure 5 (C). In summary, P3 and P12 can protect blood vessels by regulating the secretion of NO and ET-1.
[0053] Example 6: Absorption and transport mechanism of ACE inhibitory peptides based on Caco2 monolayer cell model Human colon adenocarcinoma Caco-2 cells were cultured in DMEM medium containing 20% (v / v) fetal bovine serum and 1% (v / v) penicillin / streptomycin at 37°C in an incubator containing 5% CO2. Cells were passaged every 6 days, with a passage ratio of 1:3 when cells reached over 90% confluence. The medium was changed every 3 days depending on cell growth. The cells used in the experiments were between passage 25 and 35. Caco-2 cells were seeded in 12-well Transwell chambers (0.4 μm pore size, 12 mm diameter) at a cell density of 2 × 10⁶ cells / well. 5 Cells were cultured at a density of [number] cells / mL for 21 days until complete differentiation. The integrity of the cell monolayer was assessed by measuring transepithelial electrical resistance (TEER) and alkaline phosphatase content using a Millicell ERS resistivity meter. Only TEER values greater than 350 Ω·cm were used. 2 Transport analysis was performed using a Caco-2 monolayer cell model. 0.5 mL of HBSS was added to the upper side (AP) and 1.5 mL to the lower side (BL) of the Caco-2 monolayer cells, and the cells were pre-cultured at 37°C for 30 min. Then, the HBSS solutions on the AP and BL sides were removed, and 0.5 mL of a 4 mg / mL peptide solution was added to the AP side, and 1.5 mL of HBSS was added to the BL side. For the absorption and transport inhibition assay, the Caco-2 monolayer cells were gently washed twice with preheated HBSS (pH 7.4). Gly-Sar (10 mM), cytochalasin D (0.5 μg / mL), and wollastonite (0.5 μM) were added to the AP side, and the cells were incubated at 37°C for 30 min. Then, a 4 mg / mL peptide solution was added to the AP side, and the cells were transported at 37°C for 2 h. The solutions from both sides were collected. The cells were pretreated using a solid-phase extraction column (C-18, 500 mg, 3 mL tube, ANPEL), and the peptide content was determined by high-performance liquid chromatography (HPLC). Each group was measured three times. The apparent permeability of the peptide was calculated according to the method of Grootaert et al. (Grootaert, et al., 2017), using the following formula: P app (cm / s) = dQ / (dt×A×C0) In the formula, dQ / dt is the rate at which the peptide appears at BL, and A is the surface area of the Transwell chamber (1.12 cm²). 2 C0 represents the initial concentration of the peptide in AP. The peptide transport experiment was performed, and measurements were taken at 1800 s, 3600 s, 5400 s, and 7200 s during the transport process. P App changes.
[0054] The Caco-2 monolayer cell model is often used to assess drug absorption. For example... Figure 6 As shown in Figure AB, the contents of P3 (LIVGFPAYGH) and P12 (IVGFPAYGH) on the BL side gradually increased. At 120 min, the Papp values of P3 and P12 from the AP side to the BL side were (9.37±0.43)×10⁻⁶. 7 cm / s and (9.84±0.76)×10 7 The speed of the signal (cm / s) indicates that LIVGFPAYGH and IVGFPAYGH can cross the intestinal mucosa to the serosa. Adding regulators (Gly-Sar, Wortmannin, and Cytochalasin D) to Caco-2 monolayers, Gly-Sar competitively binds to PepT1, inhibiting this peptide transporter, and is widely used in studies of competitive binding to this transporter. Wortmannin impairs endocytic vesicles, reducing peptide endocytosis. Neither Gly-Sar nor Wortmannin significantly reduced the transport of LIVGFPAYGH and IVGFPAYGH, indicating that neither PepT1 nor transcellular transport is involved in the transport of LIVGFPAYGH and IVGFPAYGH. Figure 6 (Medium CD). Furthermore, Cytochalasin D can affect tight junctions, thereby improving the cellular bypass transport of peptides. For example... Figure 6 As shown in the CD, the contents of LIVGFPAYGH and IVGFPAYGH increased significantly under the action of cytochalasin D, indicating that the peptide was passively transported from the AP side to the BL side and could be transported from the paracellular side to the serosal side through the human intestinal mucosa.
[0055] Example 7: Free Radical Scavenging Ability Test (1) DPPH free radical scavenging activity Add 0.5 mL (1 mg / mL) of the digestion product solution to 0.5 mL of 1,1-diphenyl-2-trinitrophenylhydrazine (DPPH)-ethanol solution (0.1 mM ethanol), store at 25 °C protected from light for 30 min, and then measure the absorbance at 517 nm. Each group was measured in triplicate.
[0056] DPPH free radical scavenging rate (%) = [A 0-517 -(A 1-517 -A 2-517 )] / A 0-517 ×100% In the formula, A 0-517 A 1-517 A 2-517The absorbance values are for mixtures of ethanol and DPPH solution, polypeptide solution and DPPH solution, and polypeptide solution and ethanol, respectively.
[0057] (2) Hydroxyl radical scavenging ability Mix 1 mL of 6 mM salicylic acid-ethanol solution and 1 mL of 6 mM FeSO4 solution with 1 mL of peptide solution. Then add 1 mL of H2O2 (5 mM) to the reactants and vortex mix for 10 s. Incubate at 37 °C for 60 min, and then measure the absorbance at 520 nm. Each group was measured in triplicate.
[0058] Hydroxyl radical scavenging rate (%) = [A 0-520 -(A 1-520 -A 2-520 )] / A 0-520 ×100% In the formula, A 0-520 A 1-520 and A 2-520 The absorbance values are for mixtures of water and H2O2, polypeptide solution and H2O2, and polypeptide solution and water, respectively.
[0059] (3) ABTS free radical scavenging ability Equal volumes of 7.0 mM 2,2-adiazonium diammonium salt (ABTS) solution and 2.45 mM K₂O₈S₂ solution were stored at 25 °C in the dark for 16 h. The solutions were then diluted with PBS to an absorbance of 0.70 ± 0.02 at 734 nm. 3 mL of the diluted ABTS solution was added to 0.2 mL of the peptide solution and incubated at 25 °C in the dark for 60 min. The absorbance was then measured at 734 nm. Each group was measured in triplicate.
[0060] ABTS free radical scavenging activity (%) = [A 0-734 -(A 1-734 -A 2-734 )] / A 0-734 ×100% Among them, A 0-734 A 1-734 A 2-734 The absorbance values are for mixtures of water and ABTS solution, peptide solution and ABTS solution, and peptide solution and water, respectively.
[0061] As shown in Table 3, P3 (LIVGFPAYGH) and P12 (IVGFPAYGH) exhibit free radical scavenging capabilities. The IC50 values of LIVGFPAYGH for scavenging ·OH, DPPH, and ABTS free radicals are 925.33±7.45 μM, 721.97±0.02 μM, and 153.18±0.00 μM, respectively. The IC50 values of IVGFPAYGH for scavenging ·OH, DPPH, and ABTS free radicals are 1011.43±6.73 μM, 673.07±0.01 μM, and 164.78±0.01 μM, respectively.
[0062] Table 3. In vitro antioxidant capacity IC50 values (μM) of ACE inhibitory peptides ; In summary, this invention has prepared an ACE-inhibiting peptide that has the ability to inhibit ACE activity, has better bioavailability, and has high development value and application prospects.
[0063] The above description, in conjunction with specific embodiments, provides a further detailed explanation of the present invention. It should not be construed that the specific implementation of the present invention is limited to these descriptions. For those skilled in the art, several simple deductions or substitutions can be made without departing from the concept of the present invention, and all such deductions or substitutions should be considered to fall within the scope of protection defined by the claims submitted herein.
Claims
1. An active polypeptide possessing ACE inhibitory activity and antioxidant activity, characterized in that, The amino acid sequence of the polypeptide is Leu-Ile-Val-Gly-Phe-Ala-Tyr-Gly-His or Ile-Val-Gly-Phe-Ala-Tyr-Gly-His.
2. The use of the active polypeptide according to claim 1 in the preparation of antihypertensive drugs.
3. The application according to claim 2, characterized in that, The drug also includes pharmaceutically acceptable excipients.
4. The application according to claim 3, characterized in that, The drug is in the form of granules, capsules, tablets, or injections.
